Brandon Capital — Full Portfolio

Axelia Oncology is a biopharmaceutical company developing AXA-042, a selective immunological agent designed to activate innate immune responses against checkpoint-insensitive solid tumors.

BiotechHealthtechMedical DevicesMelbourne, AU

David Jackson(Founder (Laboratory research origin))GMGrant Mchlachlan(Chief Executive Officer)

Co-investorsSTStoic VCUNUniSeed Pty Ltd.

Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions.

BiotechHealthtechMedical Devices

Luba(Director of Pre-Clinical Development)

Co-investorsOROrbiMed

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)SCScott Clarke(Chief Executive Officer)inPGPeter Garcia(Chief Financial Officer)SRSujata Rao(Chief Medical Officer)inSRStefan Ries(Chief Scientific Officer and Head of Munich Site)inAGAndrea Goddard(Chief Technical Officer)in

Co-investorsBIBioqube VenturesJEJeito CapitalFOForbionBABayern KapitalBIBioGeneration VenturesCACanaan Partners+2 more

George Medicines develops single-pill combination therapies for cardiometabolic diseases such as hypertension and diabetes, leveraging research from The George Institute for Global Health.

BiotechDigital HealthHealthtechMedical Devices

MMMark Mallon(Chief Executive Officer)inPAProfessor Anthony Rodgers(Chief Medical Officer)DKDr Karl Roberts(Chief Operating Officer)in

Co-investorsBRBrandon BioCatalystBRBrandon Capital Partners

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.

BiotechHealthtechLongevity

NMNeil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inCSClaus Sundgreen(Chief Medical Officer)inPTPaul Thompson(CDO)in

BoardJonathan Savidge(Independent Non Executive Chair)

Co-investorsCRCriteria Bio VenturesNONovartis Venture FundSVSV Health InvestorsBRBritish Business BankDEDementia DiscoveryM M Ventures+2 more

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureBIBiotechnology Value FundFOForbionLILightspeed Venture PartnersREResearch Corporation TechnologiesTCTCG Crossover

Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases.

Biotech

Co-investorsBOBooster Innovation FundCUCure Kids VenturesTETenmileBRBrandon Capital Partners

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.

BiotechDeep TechHealthtechLongevityMedical Devices

JRJane Rhodes(Chief Executive Officer)inMIMagnus Ivarsson(Chief Scientific Officer)inHPHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in

PartnerJTJonathan Tobin· solo GP

Co-investorsDEDementia Discovery FundMPMPM BioImpactNONovartis Venture FundSVSV Health InvestorsUCUCL Technology FundALAlbionVC

Biotech Dispatch is an online news publication covering the biotechnology, pharmaceutical, and medical technology industries, with a focus on Australian companies and developments.

BiotechMedia & Entertainment

BioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals.

BiotechMedia & EntertainmentMedical Devices

PartnerJTJonathan Tobin· solo GP

Co-investorsSOSound Bioventures

Brandon BioCatalyst funds biomedical development opportunities associated with its Member Institutes, offering investments ranging from AU$500,000 to AU$30 million across stages from proof-of-concept to late-stage technologies.

BiotechDeep TechDigital HealthHealthtechImpact & Social GoodMedical Devices

PartnerJTJonathan Tobin· solo GP

Co-investorsBRBrandon Capital Partners

ENA Respiratory develops and brings respiratory treatments to market across the US and other regions.

BiotechHealthtechMedical DevicesMelbourne, AU

CDChristophe Demaison(CEO)in

Co-investorsBRBrandon BioCatalystSTStoic VCUNUniSeed Pty Ltd.

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

PartnerJTJonathan Tobin· solo GP

Co-investorsKLKleiner PerkinsNENew Enterprise Associates (NEA)NENextech InvestPRProspect Venture PartnersRHRho Capital PartnersRHRho Ventures+3 more

Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.

BiotechMedical DevicesLondon, GB

Co-investorsBRBrandon Capital PartnersNONovo HoldingsSOSofinnova PartnersABAbingworth

Okogen is a clinical-stage ophthalmic pharmaceutical company developing a treatment for acute infectious conjunctivitis, covering both bacterial and viral forms.

BiotechHealthtechMedical DevicesPlano, US

JMJoshua Moriarty(Executive Officer, Director)inBSBrian Strem(Director, Promoter)Bradford Conlan(Director, Promoter)Eric J. Daniels(Executive Officer, Director, Promoter)Chris Smith(Director)Leighton Reid(Director)

Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers.

BiotechHealthtechMedical DevicesOxford, GB

ANAlan Naylor(Founder)inSHStuart Hughes(Chief Scientific Officer)in

Co-investorsCACanaan Partners

Perx develops a digital health platform that uses engagement and behavioral incentive techniques to help older patients, those with chronic conditions, and underserved populations adhere to their treatment plans and manage their health.

Digital HealthHealthtechSaaSAustralia / USA

HRHugo Rourke(CEO & Co-founder)inScott(COO & Co-founder)

Co-investorsAIAirTree VenturesGIGiant LeapSPSprint VenturesTETenmileTRTractor VenturesWIWildwood Ventures

Biotechnology company enhancing vaccine performance with its HD-MAP high-density microarray skin-delivery platform, targeting infectious disease and oncology.

Co-investorsONOneVenturesR&R&D Tax IncentiveTOTorrey Pines Investment